LC-MS/MS raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-06-09. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
=== Behavior === Glo1 expression is correlated with differences in anxiety-like behavior in mice as well as behavior in the tail suspension test, which is sensitive to antidepressant drugs; however, the direction of these effects have not always been consistent, which has raised skepticism. Differences in Glo1 expression in mice appear to be caused by a copy number variant that is common among inbred strains of mice. It has been proposed that the behavioral effects of Glo1 are due to the activity of its principal substrate methylglyoxal at GABAA receptors. A small molecule inhibitor of glyoxalase I has been shown to have anxiolytic properties, thus identifying another possible indication for inhibitors of Glyoxalase I.
For these reasons, bicalutamide has replaced spironolactone in the treatment of the condition. For comparison to bicalutamide, a higher dosage of spironolactone of 5 mg/kg (or about 100 to 150 mg in boys that are 20 to 30 kg or 45 to 65 lbs) once daily is recommended for use in male peripheral precocious puberty.
== Further reading == Batt, Reg., The Radar Army: Winning the War of the Airwaves (1991, Robert Hale, London) ISBN 0-7090-4508-5 Bragg, Michael., RDF1 The Location of Aircraft by Radio Methods 1935–1945, Hawkhead Publishing, Paisley 1988 ISBN 0-9531544-0-8 The history of ground radar in the UK during World War II Brown, Louis., A Radar History of World War II, Institute of Physics Publishing, Bristol, 1999., ISBN 0-7503-0659-9 Latham, Colin & Stobbs, Anne., Radar A Wartime Miracle, Sutton Publishing Ltd, Stroud 1996 ISBN 0-7509-1643-5 A history of radar in the UK during World War II told by the men and women who worked on it. Latham, Colin & Stobbs, Anne., Pioneers of Radar (1999, Sutton, England) ISBN 0-7509-2120-X Scanlan, M.J.B., Chain Home Radar - A Personal Reminiscence, The General Electric Company, p.l.c., GEC Review, Vol. 8, No. 3, 1993, p171-183, ISSN 0267-9337 Zimmerman, David., Britain's Shield: Radar and the Defeat of the Luftwaffe, Sutton Publishing Ltd, Stroud, 2001, ISBN 0-7509-1799-7
== Research == In 1960 he commenced work in Cambridge on his PhD degree under the supervision of Fred Hoyle, and published his first scientific paper "On Graphite Particles as Interstellar Grains" in Monthly Notices of the Royal Astronomical Society in 1962. He was awarded a PhD degree in mathematics in 1963 and was elected a Fellow of Jesus College Cambridge in the same year. In the following year he was appointed a Staff Member of the Institute of Astronomy, Cambridge. Here he continued to work on the nature of interstellar dust, publishing many papers in this field, that led to a consideration of carbon-containing grains as well as the older silicate models. Wickramasinghe published the first definitive book on Interstellar Grains in 1967. He has made many contributions to this field, publishing over 350 papers in peer-reviewed journals, over 75 of which are in Nature. Hoyle and Wickramasinghe further proposed a radical kind of panspermia that included the claim that extraterrestrial life forms enter the Earth's atmosphere and were possibly responsible for epidemic outbreaks, new diseases, and genetic novelty that Hoyle and Wickramasinghe contended was necessary for macroevolution. Chandra Wickramasinghe had the longest-running collaboration with Fred Hoyle. Their publications on books and papers arguing for panspermia and a cosmic hypothesis of life are controversial and, in particular detail, essentially contra the scientific consensus in both astrophysics and biology.
Sources: en.wikipedia.org
(WINNER) The contestant won the whole competition. (WIN) The contestant won the Haunted Heat (HIGH) The contestant had one of the best dishes in the Haunted Heat. (IN) The contestant performed well enough to move on to the next week. (RISK) The contestant had one of the bottom dishes in the Haunted Heat and competed in the Bake for Your Life challenge, but was not eliminated. (LOW) The contestant had one of the bottom dishes in the episode's only challenge but was not eliminated. (OUT) The contestant was eliminated for worst dish. (WDR) The contestant withdrew from the competition.
== Selected works == Marks, Vincent; Rose, Frank Clifford (1965). Hypoglycaemia. Blackwell. Marks, Vincent; Feldman, Stanley (2006). Panic Nation: Exposing the myths we're told about food and health. Kings Road Publishing. ISBN 978-1-85782-840-5. Marks, Vincent; Richmond, Caroline (2007). Insulin Murders. Taylor & Francis. ISBN 978-1-85315-760-8. Marks, Vincent; Cantor, Thomas; Mesko, Dusan; Pullmann, Rudolf; Nosalova, Gabriela (2012). Differential Diagnosis by Laboratory Medicine: A Quick Reference for Physicians. Springer Science & Business Media. ISBN 978-3-642-55600-5. Hubbard, Ron; Marks, Vincent (2013). Clinical Applications of Monoclonal Antibodies. Springer Science & Business Media. ISBN 978-1-4613-1573-5.
Animal products such as meat, fish, shellfish, fowl, eggs, and dairy contain zinc. The concentration of zinc in plants varies with the level in the soil. With adequate zinc in the soil, the food plants that contain the most zinc are wheat (germ and bran) and various seeds, including sesame, poppy, alfalfa, celery, and mustard. Zinc is also found in beans, nuts, almonds, whole grains, pumpkin seeds, sunflower seeds, and blackcurrant. Other sources include fortified food and dietary supplements in various forms. A 1998 review concluded that zinc oxide, one of the most common supplements in the United States, and zinc carbonate are nearly insoluble and poorly absorbed in the body. This review cited studies that found lower plasma zinc concentrations in the subjects who consumed zinc oxide and zinc carbonate than in those who took zinc acetate and sulfate salts. For fortification, however, a 2003 review recommended cereals (containing zinc oxide) as a cheap, stable source that is as easily absorbed as the more expensive forms. A 2005 study found that various compounds of zinc, including oxide and sulfate, did not show statistically significant differences in absorption when added as fortificants to maize tortillas.
Sources: en.wikipedia.org
=== Ether lipids in bacteria === Though archaeol, featuring the ether linkage between isoprenoid chain to glycerol, has been considered as a biomarker for archaea, ether membrane lipids have also been discovered in some aerobic and anaerobic bacteria, including lipids with one ester bond and one ether bond to alkyl chains. Many strictly anoxic bacteria and a few aerobic species contain plasmalogens (Pla), which has an alkyl chain bound to sn-1 position of the glycerol via a vinyl-ether bond. Similar to archaea, these lipids are thought to increase the resistivity of bacteria to adverse environments. More stunning is the discovery of nonisoprenoid dialkyl glycerol diether lipids (DGD) and branched dialkyl glycerol tetraether lipids (brGDGT), which are formed, in the similar way to archaeol, by binding alkyls chains (but not isoprenoid chains) to glycerol molecules via ether linkage. It's highly notable that these lipids are only different from archaea ether lipids in the side chains and binding positions on the glycerol. DGD is reported in thermophilic bacteria, a few mesophilic bacteria and aggregating myxobacteria. In 2018, a group from the University of Groningen managed to produce a large amount (30% of total phospholipids) of true archaeol-based phospholipid in transgenic E. coli. They found that the modified cells show higher tolerance to heat and cold. The result builds on top of their earlier 2015 attempt, which produced only a minuscule amount.
== Diagnosis == Myasthenia gravis can be difficult to diagnose, as the symptoms can be subtle and hard to distinguish from both normal variants and other neurological disorders. Three types of myasthenic symptoms in children can be distinguished:
(Rateable Values) (Scotland) Order 1993 (S.I. 1993/878) British Gas plc. (Rateable Values) (Scotland) Order 1993 (S.I. 1993/879) British Railways Board (Rateable Values) (Scotland) Order 1993 (S.I. 1993/880) British Telecommunications plc. (Rateable Values) (Scotland) Order 1993 (S.I. 1993/881) Glasgow Underground (Rateable Values) (Scotland) Order 1993 (S.I. 1993/882) Lochaber Power Company (Rateable Values) (Scotland) Order 1993 (S.I. 1993/883) Mercury Communications Ltd. (Rateable Values) (Scotland) Order 1993 (S.I. 1993/884) Mines and Quarries (Rateable Values) (Scotland) Order 1993 (S.I. 1993/885) Water Undertakings (Rateable Values) (Scotland) Order 1993 (S.I. 1993/886) National Health Service Act 1977 (Composition of Medical Practices Committee) Modification Order 1993 (S.I. 1993/887) A1 Trunk Road (Islington) Red Route Traffic Order 1993 (S.I. 1993/891) United Kingdom Central Council for Nursing, Midwifery and Health Visiting (Legal Assessors) (Amendment) Order 1993 (S.I. 1993/892) Nurses, Midwives and Health Visitors (Professional Conduct) Rules 1993 Approval Order 1993 (S.I. 1993/893) Non-Domestic Rating (Collection and Enforcement) (Amendment and Miscellaneous Provision) (No. 2) Regulations 1993 (S.I. 1993/894) A1 Trunk Road (Islington) (Bus Lanes) Red Route Traffic Order 1993 (S.I. 1993/895) A1 Trunk Road (Haringey) Red Route Traffic Order 1993 (S.I. 1993/896) A1 Trunk Road (Haringey) (Bus Lanes) Red Route Traffic Order 1993 (S.I. 1993/897) Act of Sederunt (Fees of Solicitors in the Sheriff Court) (Amendment) 1993 (S.I.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.